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A Ab bs st tr ra ac ct t
The Human Gene Mutation Database (HGMD® ®) is a comprehensive core collection of germline
mutations in nuclear genes that underlie or are associated with human inherited disease. Here,
we summarize the history of the database and its current resources. By December 2008, the
database contained over 85,000 different lesions detected in 3,253 different genes, with new
entries currently accumulating at a rate exceeding 9,000 per annum. Although originally
established for the scientific study of mutational mechanisms in human genes, HGMD has since
acquired a much broader utility for researchers, physicians, clinicians and genetic counselors as
well as for companies specializing in biopharmaceuticals, bioinformatics and personalized
genomics. HGMD was first made publicly available in April 1996, and a collaboration was initiated
in 2006 between HGMD and BIOBASE GmbH. This cooperative agreement covers the exclusive
worldwide marketing of the most up-to-date (subscription) version of HGMD, HGMD
Professional, to academic, clinical and commercial users.
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The Human Gene Mutation Database (HGMD®) [1] records
the first report of a disease-causing mutation or disease-
associated/functional polymorphism and provides these
data in a readily accessible form to all interested parties,
whether they are from an academic, a clinical or a
commercial background. HGMD has become the de facto
central disease-associated mutation database available to
the scientific community. The data comprise single base-pair
substitutions in coding, regulatory and splicing-relevant
regions of human nuclear genes, micro-deletions and micro-
insertions, combined insertions/deletions (indels), repeat
expansions, gross lesions (deletions, insertions and duplica-
tions) and complex rearrangements (including inversions).
These categories of mutation data are summarized in Table 1.
Mutation and polymorphism data are obtained by means of
a combination of manual and computerized search proce-
dures. Thus, online library screening, the PubMed database
and publicly available locus-specific mutation databases
(LSDBs) are all used to optimize data acquisition. Each
mutation or disease-associated/functional polymorphism is
entered into HGMD only once under its earliest literature
citation. Silent mutations within the coding region that do
not alter the encoded amino acid are not recorded unless
there is clear evidence of altered splicing and/or a direct
disease association. Mutations that have not been ade-
quately or unambiguously described in the corresponding
literature report are also excluded unless full details can sub-
sequently be obtained from the authors. Disease-associated/
functional polymorphisms (see below) are excluded if the
published data are deemed to be of insufficient quality (either
because of the description provided or because of a tenuous/
non-significant association with a clinical or laboratory
phenotype). HGMD does not include somatic lesions or
mitochondrial genome mutations. These are well covered by
COSMIC [2] and MITOMAP [3], respectively.
Mutation data are viewable on a gene-wise basis and access
to the subcategorized mutation data is available via hyper-
text link from each gene page. Additional links tocomplementary data sources are provided here (Genome
Database (GDB) [4], Online Mendelian Inheritance in Man
(OMIM) [5], HUGO Gene Nomenclature Committee (HGNC)
[6], Entrez Gene [7], GeneCards [8], GenAtlas [9],
GeneClinics [10], UniGene [11], SwissProt [12] and the
Human Protein Reference Database [13]). HGMD also
provides annotated cDNA sequences for over 95% of the
genes present in the database. The annual number of new
entries being logged in HGMD has been steadily increasing
over the last few years (Table 2) and now stands at over
9,000 mutations per annum. The number of new genes being
entered into HGMD has also followed this upward trend, with
441 new genes being introduced during 2007 alone.
D Di is se ea as se e- -a as ss so oc ci ia at te ed d/ /f fu un nc ct ti io on na al l   p po ol ly ym mo or rp ph hi is sm ms s
In addition to disease-causing mutations, HGMD seeks to
include polymorphic DNA sequence variants that are either
disease-associated and of direct functional significance, or of
clear functional significance even though an associated
clinical phenotype has yet to be identified. At present, these
polymorphic variants comprise about 5% of HGMD data and
approximately 55% of these are ‘disease-associated’. The
remainder represent variants that, despite manifesting no
demonstrable disease association, have nevertheless been
shown to significantly alter the expression of a gene or the
structure/function of the gene product. Although functional
polymorphisms with no known disease association do not
have any immediate clinical relevance, these data are
potentially very valuable in terms of understanding inter-
individual differences in disease susceptibility.
Although the vast majority of polymorphic variants in
HGMD are single-nucleotide polymorphisms (SNPs), a
small number are of the insertion/deletion type. The poly-
morphic variants logged in HGMD are generally located in
either the gene promoter or coding regions. However, it
should be noted that SNPs occurring outside of these regions
may nevertheless still have consequences for gene expres-
sion, splicing or transcription-factor binding. Polymorphic
variants affecting individual drug response [14], patient
survival times after diagnosis and responses to surgical
intervention are not generally included in HGMD. Studies
that simply report SNPs [15] in association with disease (and
hence are likely to represent merely a linkage disequilibrium
effect), but with no additional evidence of direct functional
involvement of the variants in question, are also not
included. Reports of haplotypes associated with an increased
risk of disease are not included unless there is some
indication as to precisely which variant(s) within the
haplotype is/are responsible for the disease association or
functional effect.
In some instances, the above criteria may be only partially
satisfied, such that the HGMD curators remain unconvinced
as to the clinical phenotypic relevance of the reported poly-
morphic variant. In such cases, the polymorphism may
nevertheless still be included (i) as a result of supporting
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Number of entries
HGMD professional 
Mutation type HGMD public version (subscription version)
Single base-pair substitutions
Missense or nonsense 35,545 48,343
Splicing 5,803 8,219
Regulatory 817 1,400
Other lesions
Small (≤20 bp) deletions 10,035 13,628
Small (≤20 bp) insertions 4,014 5,567
Small (≤20 bp) indels 909 1,244
Large (>20 bp) deletions 3,536 5,158
Large (>20 bp) insertions and duplications 559 1,003
Complex rearrangements (including inversions) 453 736
Repeat variations 151 260
Total 61,822 85,558information becoming available subsequent to the publica-
tion of the original report, or (ii) because the associated
gene/disease state was deemed to be of sufficient importance
for it to warrant further study. Such variants are generally
ascribed the descriptor ‘association with?’ to indicate that
some degree of uncertainty is involved. The difficulty
inherent in making decisions regarding the inclusion or
exclusion of variants that have potential disease associations
highlights the need for a methodical and methodologically
uniform approach to assessing such reports as they appear in
the literature [16].
Several other databases [17-19] have attempted to collate
known polymorphism-disease associations but have met
with only partial success owing to an over-reliance on
computerized search procedures and automated data
collection. This methodology tends to result in the creation
of a database that comprises either verbatim and/or often
inconsistent records of the disease-associated variants, or
merely a list of PubMed citations rather than the actual
variants in question. Polymorphism-disease association data
curated in this way are also likely to comprise markers that
occur in linkage disequilibrium with the presumed disease-
associated/functional variants rather than being of
functional significance themselves. We on the HGMD team
believe that a manually curated database provides a rather
better solution. Indeed, HGMD is currently the only
database that focuses specifically on the collation of
functional/disease-associated polymorphic variants to the
exclusion of linkage markers.
A current limitation with regard to recording disease-
associated polymorphic variants of functional significance
within HGMD is the inclusion of only a single literature
reference for each variant. A large proportion of those
papers reporting a novel association between a disease and a
polymorphic variant do not include functional data on that
variant. HGMD will in the future address this by
implementing a dual referencing system for polymorphisms:
reference 1 will correspond to the first report demonstrating
a functional effect (or disease-association) that meets the
HGMD inclusion criteria, whereas reference 2 will (where
appropriate) provide evidence of the first disease-association
(or functional effect) of the polymorphism.
H HG GM MD D   f fu un nd di in ng g
Since HGMD does not receive any public funding to support
its upkeep, it has been necessary to develop a sustainable
model for both the current and future funding of the
database. The ideal model (in the opinion of the curators)
would be a mixture of income from both public and private
sources. This, in principle, would allow HGMD to provide
free database access to academic/non-profit users alongside
a subscription-based distribution for commercial users
marketed by a commercial company. With this eventual aim
in mind, the HGMD curators opted to market their data in
collaboration with BIOBASE GmbH [20]. As part of the
commercial agreement, Cardiff University, as HGMD’s host
institution, agreed to provide BIOBASE with a period of
exclusive access to newly added mutational information.
This period extends to 2.5 years from the date of initial
inclusion. BIOBASE provides HGMD (in the form of HGMD
Professional; see below) as a stand-alone product as part of
its database subscription package. The publicly available
version of HGMD will, however, continue to be made avail-
able as a free service to registered users from academic/non-
profit institutions via the Cardiff website [1]. By insisting
that commercial entities pay for access to the latest HGMD
data and software tools, while still providing a less up-to-
date version free of charge to registered users from
academic/non-profit institutions, the HGMD curators
believe that they can continue to allow free access to the bulk
of their mutation data, at the same time as generating
sufficient income to support the maintenance of HGMD
from its commercial distribution.
H HG GM MD D   u us se er rs s   a an nd d   u us sa ag ge e
HGMD has recently introduced a user registration scheme,
which is free for users from academic/non-profit organiza-
tions. Prior registration is required to access and use HGMD.
After completing the registration form, users are sent a
password by email, which they can use to log on to the public
HGMD website. Since the inception of the system in April
2006, over 23,000 user registrations have been recorded
and HGMD is continuing to accrue about 800 new regis-
trations every month. We have registered users from over
150 different countries (Table 3), providing an indication of
how widely HGMD is used by the academic community
worldwide. Each month, an average of 14,000 queries for
genes are received (with an equal number accessing HGMD
genes via an external link) from almost 6,000 users, with a
total of over 160,000 pages served.
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Number of new  Number of new 
Year mutation entries gene entries
2001 7,451 189
2002 5,849 197
2003 5,989 214
2004 5,657 257
2005 7,649 241
2006 9,901 287
2007 9,371 441
2008 (to 1 December)  9,006 353Users of the public site may not download HGMD data in
their entirety without permission. This is, however, generally
granted if the data are to be used exclusively for non-
commercial collaborative research purposes. Collaborators
who wish to access HGMD data in full are required to sign a
confidentiality agreement. Recent successful collaborations
include the projects to sequence the genomes of Macaca
mulatta [21] and Rattus norvegicus [22] and a study into
gains of glycosylation as a cause of inherited disease [23].
HGMD data have also been used by researchers in several
other studies, including the newly reported sequencing of
diploid genomes from individual humans [24,25] and recent
mutation [26] and evolutionary [27] studies.
H HG GM MD D   P Pr ro of fe es ss si io on na al l
HGMD Professional [28] has been developed to serve as the
subscription version of HGMD, and is available to both
commercial and academic customers through a license from
BIOBASE, our commercial partner. The Professional
version allows access to up-to-date mutation data, with an
updated product release every 3 months. This version is
therefore essential for checking the novelty and/or patho-
genicity of mutations newly found by researchers, clinicians
and diagnosticians.
HGMD Professional contains many features not available in
the free public version [29]. More powerful search tools in
the form of an expanded search engine with full text Boolean
searching are provided. Users can use these tools to perform
additional searches for chromosomal locations, Entrez Gene
ID numbers [7], HGNC database ID numbers [6], common
gene symbol aliases [7], codon numbers, HGMD accession
numbers and literature references. Enhanced gene and
mutation viewing is also enabled, allowing improved naviga-
tion between different genes and mutation types.
Additional information is also provided on a mutation-
specific basis. This includes curatorial comments pertaining
to particular mutations (for example if the mutation data
required correction in relation to the data presented in the
original publication), and comparative biochemical informa-
tion (including change in residue polarity, pH, weight,
hydrophobicity [30,31], secondary structure propensity [32]
and Grantham difference [33]) for the amino acid sub-
stitutions. These data are intended to assist with the assess-
ment of the likely pathogenicity of each missense mutation.
Pairwise alignments (21 amino acids long) are also provided
for the majority of missense mutations in HGMD, using
orthologous protein sequences obtained from the Entrez
protein  database [34]. In this context, HGMD Professional
currently contains protein sequences from Mus musculus,
Rattus norvegicus, Gallus gallus,  Canis lupus familiaris,
Felis catus,  Sus scrofa,  Ovis aries,  Bos taurus,  Takifugu
rubripes, Pan troglodytes and Macaca mulatta. Amino acid
sequences will continue to be added as they appear in the
Entrez protein database. This feature allows HGMD users to
ascertain the evolutionary conservation of a given amino
acid residue and its surrounding sequence in relation to each
missense mutation without having to load mutated
sequences from HGMD into an external database.
A Ad dv va an nc ce ed d   s se ea ar rc ch h   t to oo ol ls s
The Advanced Search is essentially a suite of software
tools, available as part of HGMD Professional, which are
designed to enhance mutation searching, viewing and
retrieval. Two of the main types of mutation in HGMD
(single-nucleotide substitutions and microlesions ) can be
interrogated with this toolset. The datasets of each
mutation type can be combined (for example, micro-
deletions, microinsertions and indels) to enable more
powerful searching across comparable types of mutation.
When using the Advanced Search, users can tailor their
queries with more specific criteria, including amino-acid
exchange; nucleotide substitution; the size of a micro-
deletion, microinsertion or indel; composition; motifs
(both those created and those abolished by the mutation);
dbSNP number; and keywords in the article title or
abstract. Any mutation results returned by the Advanced
Search can be downloaded in a tab-delimited format, ready
to import into a different application.
http://genomemedicine.com/content/1/1/13 Genome Medicine 2009, Volume 1, Issue 1, Article N13 Stenson et al. 13.4
Genome Medicine 2009, 1 1: :13
T Ta ab bl le e   3 3
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( (a as s   o of f   1 1   D De ec ce em mb be er r   2 20 00 08 8) )
Country Number of registrations
United States 5,647
China (including Hong Kong) 2,053
United Kingdom 1,949
Italy 1,340
India 1,072
Germany 891
Spain 857
Japan 786
France 746
Australia and New Zealand 778
Canada 646
Rest of Europe 3,129
Rest of Asia (including Middle East)  2,640
Central and South America 920
Africa 306
Others 11
Total 23,771Part of the Advanced Search tool includes a dynamic
mutation viewer, which depicts coding-region mutations
superimposed on the cDNA sequence of a gene. The wild-
type cDNA sequence is represented in black whereas the
mutated nucleotides are shown in different colors according
to the type of mutation. Displays of each mutation type can
be switched on or off using the appropriate buttons.
F Fu ut tu ur re e   d di ir re ec ct ti io on ns s   f fo or r   H HG GM MD D
We have recently incorporated a fully comprehensive
functional/disease-associated polymorphism dataset into
HGMD to complement the existing disease-causing mutation
data. The provision of additional orthologous protein
sequences for alignments, fully annotated genomic sequences
for all HGMD genes, and genomic coordinates for as many
mutations as possible are also seen as high priorities.
The provision of further supplementary information,
including additional clinical phenotypes observed with a
given mutation, multiple additional references and gene and
disease ontologies and in vitro characterization data will be
added to HGMD once resources permit.
We believe that the development of HGMD Professional
together with the suite of Advanced Search tools provides
the user with a unique resource that can be used not only to
acquire evidence to support the pathological authenticity
and/or novelty of detected lesions, but also to obtain an
overview of the mutational spectra for specific genes. It is
hoped that these new developments will not only help to
secure the future of HGMD, but will also enhance the
facilities currently used for the long term storage and
provision of mutation data to the scientific community.
A Ab bb br re ev vi ia at ti io on ns s
DbSNP, The Entrez Single Nucleotide Polymorphism data-
base; GDB, Genome Database; HGMD, Human Gene
Mutation Database; HGNC, HUGO Gene Nomenclature
Committee; HUGO, Human Genome Organisation; LSDB,
Locus-specific Mutation Database; OMIM, Online Mendelian
Inheritance in Man; SNP, single-nucleotide polymorphism.
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The authors wish to declare that HGMD is in receipt of
funding from BIOBASE GmbH [2], their commercial
partner. HGMD Professional, a version of the database that
includes a suite of advanced analytical/search tools, is only
available via subscription through BIOBASE. All financial
support received from BIOBASE is used exclusively for the
upkeep and maintenance of HGMD.
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